📰 Bill Guyer News
Bill Guyer News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Bill Guyer. Real-time updates on events, politics, business and more.
May 28, 2024
MENLO PARK, Calif., May 28, 2024 -- Corcept Therapeutics Incorporated , a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic,...
May 28, 2024
Relacorilant was associated with sustained improvements in hypertension among patients with Cushing syndrome, according to results from the phase 3 GRACE trial.
May 28, 2024
Relacorilant achieves primary endpoint in phase 3 GRACE trial among patients with hypercortisolism and hyperglycemia, hypertension or both, with sNDA expected in Q3 2024.
May 1, 2024
Revenue and Earnings Surge Amid Expanding Market Presence
April 22, 2024
MENLO PARK, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...
April 8, 2024
MENLO PARK, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in t...
April 1, 2024
MENLO PARK, Calif., April 01, 2024 -- Corcept Therapeutics Incorporated , a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic,...
April 1, 2024
MENLO PARK, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced completion of enrollment in GRADIENT, a Phase 3 trial of its proprietary selective cortisol modulator relacorilant in patients with Cushing’s syndrome (hypercor...
February 15, 2024
MENLO PARK, Calif., Feb. 15, 2024 -- Corcept Therapeutics Incorporated , a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic,...
February 15, 2024
MENLO PARK, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...